The filing is a routine advance notice of a director's intent to sell shares acquired through option exercise. The sale amount is modest relative to typical director holdings. Monitor for any subsequent Form 4 filings to confirm execution and for any pattern of insider selling.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $105.35entry
- T+1 · 19h ago −5.80%α −3.89% · $99.24
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Kristine Ball filed a Form 144 notice of intent to sell 18,000 shares of Oruka Therapeutics common stock, with an estimated aggregate market value of approximately $1.93 million. The shares were acquired via stock option exercise on the same date. The sale represents a modest portion of the director's holdings and is not unusual for a director-level insider.
Key Facts
- Kristine Ball, a director, filed Form 144 to sell 18,000 shares of common stock.
- Estimated aggregate market value of the proposed sale is $1,929,060.
- Shares were acquired on 11/12/2026 via exercise of stock options from the issuer.
- The proposed sale date is 11/12/2026, the same day as the filing.
- The sale is to be executed through Morgan Stanley Smith Barney LLC.
Financial Impact
18,000 shares at approximately $107.17 per share, totaling about $1.93 million.
Risk Factors
- Insider selling, even if routine, can signal reduced conviction if it becomes a pattern.
- Form 144 is an intent to sell; the actual sale may not occur.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-011029 |
| Document: 0001950047-26-011029-index.html | 0001950047-26-011029 |
| Document: 0001950047-26-011029.txt | 0001950047-26-011029 |
Track record
40 reports on ORKA
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers